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Abstract
Background/Aims: The LDL receptor-related protein-1 gene (LRP-1) has been associated with obesity in animal models, but
no such association has yet been reported in humans. As data suggest this increase in fat mass may be mediated through a
mechanism involving the clearance of plasma triglyceride-rich lipoproteins (TGRL), where the LRP interacts with
apolipoprotein E (ApoE) on chylomicron remnants, we aimed to examine (1) whether there was an association between 3
single nucleotide polymorphisms (SNPs) on LRP-1 with body mass index (BMI) and (2) whether any association between LRP-
1 SNPs and BMI could be modified by polymorphisms on the ApoE gene when comparing the wild type e3/e3 genotype
against mutant ApoE allele (e2/e4) carriers.
Methods/Results: We used data from 1,036 men and women (mean age6SD=49616 y) participating in the Genetics of
Lipid Lowering Drugs and Diet Network (GOLDN) Study. Mixed linear models, which controlled for age, sex, alcohol intake
and smoking, as well as family pedigree and center of data collection were calculated. Models that used LRP-1 genotype as a
predictor of BMI revealed that individuals who were homozygous for the minor allele at the LRP-1 I10701 locus had BMIs, on
average, 1.03 kg/m
2 higher than major allele carriers (P=0.03). In subsequent mixed linear models that included main
effects of LRP-1 I10701 SNP and ApoE alleles, and an interaction term the two genotypes, there was no interaction detected
between the LRP-1 I70701 genotype with either the ApoE e2o re4 allele carriers (P.0.05).
Conclusions: This has implications for starting to understand pathways from genotype to human BMI, which may operate
through TGRL uptake at the LRP-1 receptor. This may pave the way for future research into individualized dietary
interventions.
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Introduction
The role of the LRP, alongside that of the LDL receptor, in the
uptake of chylomicron remnants has long been established [1]. The
LRP-1 gene is expressed in a number of tissues, including the liver,
the primary site of LRP-mediated chylomicron remnant clearance
[2]. In vitro LRP-1 elimination has been shown to lead to lipid
depleted cells [3] and LRP-1 knockout mice show fat storage
differences compared to wildtype mice, although results have been
bidirectional [3–6]. Changes in fat mass in LRP-1 knock-out mice
are thought to occur, in part, through the reduced catabolism and
uptake of TGRL [4]. The reduced clearance, and subsequent
accumulationof TGRL hasbeensimilarlyassociated with increased
fat mass in humans [7], yet to our knowledge, an association
between human BMI and LRP-1 variants has yet to be reported.
To enable chylomicron remnant binding and subsequent uptake,
the LRP-1 binds with ApoE on the surface of remnant particle [2,8,9].
Three major isoforms of ApoE exist (E2, E3 and E4) which are the
products of three alleles (e2, e3a n de4, respectively) at the single gene
ApoE locus. Variations in ApoE isoforms have been associated with
variation in the efficacy of ApoE binding to receptor sites [10] and,
from this, with differing lipid profiles. Meta-analysis across 45
population samples confirmed the differential effects of the ApoE
alleles on lipids; carriers of e2 had lower, and carriers of e4 had higher,
fasting plasma cholesterol values compared to e3/e3 genotypes [11].
The effect of different ApoE isoforms on lipids and LRP-1 mediated
TGRL uptake, indicates that ApoE remains a promising candidate to
s t u d yf o re f f e c t so nB M I ,i nc o n j u c t i o nw i t hLRP-1 polymorphisms.
The first aim of these analyses was to evaluate an association
between three polymorphisms on the LRP-1 gene and body mass
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and women between the ages of 18–87 years. The second aim was
to examine whether any association between BMI and LRP-1
identified in our sample was modified by ApoE allelic variants.
Materials and Methods
Participants
The GOLDN study population consisted of 1,328 men and
women in the Genetics of Lipid-Lowering Drugs and Diet
Network (GOLDN) study. All participants were white men and
women recruited from Minneapolis, Minnesota and Salt Lake
City, Utah. The primary aim of the GOLDN study was to
characterize the role of genetic and dietary factors on an
individual’s response to fenofibrate. The details of the GOLDN
study have been published elsewhere [12]. GOLDN consisted of
an initial screening visit (visit 0) during which participants were
asked to discontinue the use of lipid lowering drugs. Approxi-
mately 4 to 8 weeks later, baseline blood chemistries were
measured (visit 1). A day later (visit 2) participants’ blood samples
were collected before (fasting) and after (postprandial) participating
in a high fat meal challenge. On subsequent visits 3 and 4, fasting
and postprandial blood samples were collected after a 3-week open
label fenofibrate trial. For this analysis, we used blood draw and
BMI data collected at visit 2. This includes data only from subjects
who were willing to participate in the high fat meal intervention.
The final sample consisted of 1036 individuals across 187 families;
497 men and 539 women (mean 6 SD: 48.8616.2 y of age). The
protocol was approved by the Institutional Review Boards at the
University of Minnesota, University of Utah, Tufts University/
New England Medical Center, and the University of Alabama at
Birmingham. Written informed consent was obtained from all
participants.
Data collection
Clinical characteristics including anthropometric and blood-
pressure measurements were taken at the study clinics where a
fasting blood sample (used for the genotyping) was also drawn, as
described previously [12]. Questionnaires were administered to
collect demographic data and information on lifestyle attributes
and medical history.
Measures
Anthropomorphic and demographic measures. BMI
data were collected by trained research staff who were instructed
to take weight measurements over light clothing. BMI was
measured as weight in kilograms (kg) divided by height in meters
squared (m
2). Age and sex were recorded by questionnaire.
Habitual alcohol (g/day) and smoking behavior (current/non) was
measured by the dietary history questionnaire (DHQ).
Genotype data. Genomic DNA was isolated from blood
samples using routine DNA isolation sets (Qiagen, Valencia, CA,
USA), using a TaqMan assay with allele-specific probes on the
ABI Prism 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) according to the
standardized laboratory protocols.
SNP selection. Three nonsynonymous SNPs on the LRP-1
gene on Chromosome 12 (positions 12q13.1-q13.3) were chosen
from literature reports of genetic associations or lipid-related
biological function [13–15].These were C766T (rs1799986) in
exon 3, I68477 (rs1800191) in intron 55 and I10701 (rs715948) in
intron 2. SNAP from the Broad Institute (http://www.
broadinstitute.org/mpg/snap/index.php) indicated that none of
the SNPs were in linkage disequilibrium with r..8.
The ApoE alleles were typed at the previously identified ApoE
locus. Given that e2 carriers and e4 carriers have both shown
effects on lipid measures in comparison to e3, but their effects may
not be in the same direction [11], we compared e2 carriers
(without including e4 carriers) to those with the e3/e3 genotype
and separately: e4 carriers (without including e2 carriers) to those
with the e3/e3 genotype.
As we were interested at the theoretical level of how ApoE
isoforms mediate the effects of LRP-1 SNPs, only those LRP-1
SNPs which showed an effect on BMI as a significant association
with BMI were examined for mediation by ApoE alleles.
Statistical analysis
All analyses were conducted in SAS (v9.2; SAS Institute, Cary,
NC). Hardy-Weinberg equilibrium (HWE) was determined using
x
2 goodness-of-fit analysis. All SNPs were in HWE (p..05). For
genotype-phenotype associations examining a main effect of the
LRP-1 SNPs on BMI, regression analysis was conducting using the
‘‘PROC MIXED’’ command with genotypes modeled as a
dominant effect, age and age
2, sex, smoking (measured as current
smoker or non-smoker), average total alcohol consumption/day,
and center of data collection as predictors, and BMI (logarithmi-
cally transformed) as the outcome. Pedigree membership was
treated as a random effect. To test for gene-gene interactions, the
same model was run, and we additionally included APOE genotype
as a predictor and an interaction term between LRP-1 and APOE
genotypes. To control for differences in group variances a
Kenward Roger approximation to the degrees of freedom for
the reference distribution was applied [16].
Results
Participant characteristics
Table 1 shows allele frequencies, APOE genotype frequencies,
age and sex by LRP-1 genotype.
Main effects of LRP-1 on BMI
An examination of BMI by genotype frequencies suggested
dominant modes of inheritance for the effects of LRP-1 on BMI
(Table 2). In mixed linear models that compared major allele
carriers to those homozygous for the minor allele, while controlling
for the covariates previously described, the rs1799986 and
rs1800191 SNPs were not significantly associated with BMI
(P..05; Table 2). However, carriers of the major allele of
rs715948 had BMIs, on average, 1.03 kg/m
2 higher than those
homozygous for the minor allele(P=.03). However, this unadjusted
P-value did not remain significant after a Bonferroni correction for
multiple testing was applied.
Interactions between LRP-1 rs715948 and APOE
genotypes on BMI
Frequencies of e2 carriers and e3/e3 genotypes by LRP-1
rs715948 locus genotypes are shown in Table 3. For those who
carried the effect of the major allele at the LRP-1 rs715948 locus,n o
significant interaction was observed with ApoE genotype (Table 4).
Discussion
In a large, epidemiological cohort we examined three SNPs on
the LRP-1 gene for associations with BMI, and an interaction with
ApoE genotype that may modify this association. We report that
overall, the major allele of the rs715948 SNP was associated with
BMIs 1.03 kg/m2 higher than those without the major allele, and
LRP, ApoE and BMI
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genotype.
Previously, LRP-1 knockout mice have been associated with
poorer TGRL clearance, although the direction of effect on BMI
is not clear. Hoffman et al report LRP-1 knockout mice to have a
lower fat mass, which in addition to the observed elevated energy
expenditure, was attributed reduced postprandial TGRL uptake
[4]. However, although Liu et al report similar perturbations in
postprandial TGRL clearance, they found LRP-1 knockout mice
to be associated with a 2-fold increase in fat mass compared to
wild-type mice, coinciding with an ‘obese phenotype’ which
included increased food intake, reduced energy expenditure and
decreased leptin [5]. Their association of LRP-1 knockout mice
with increased fat mass was supported by work by Terrand et al,
who found LRP-1 knockout mice to show increased body fat
arising from reduce lipolysis [6]. Although LRP-1 has been shown
to be upregulated in obese human adipose tissue [3], and increased
concentrations of TGRL, such as chylomicron remnants, have
been implicated in obesity in humans [7], this is the first study, to
our knowledge, to report an association between LRP-1 variants
and BMI in humans. We report a significant association between
SNP rs715948 in intron 2 of the LRP-1 gene (P=.03). This SNP is
in the cholesterol-lowering pathway, has previously been associ-
ated with cholesterol responses to statin therapy [17], but not to
other lipid or obesity-related phenotypes in humans. Animal
models suggest that impaired receptor-mediated TGRL chylomi-
cron remnant clearance in conjunction with decreased energy
expenditure and lipolysis may, in part, explain the 1.03 difference
in BMI we observed between those homozygous for the minor
allele and carriers of the major allele at the I10701 locus on the
LRP-1.
We observed that the association between the LRP-1 rs715948
SNP was not significantly modified by carrying either the e2 nor
the e4 allele at the ApoE locus. Therefore, the binding of the LRP-
1 receptor to the isoform of ApoE on the chylomicron is not
suggested as the mechanism by which LRP-1 variants affect BMI.
A closer examination of postprandial TGRL would confirm such
findings.
Table 1. N, mean age (standard deviation) and percentage of
males and ApoE e3 carriers, in the GOLDN study population
by LRP-1 genotype group.
Genotypes{ P{
aa aA AA
C766T
N 16 246 771
Gender, % male 31.25 45.93 48.9 0.29
Age, y 48.83 (14.84) 49.55 (16.12) 48.50 (16.24) 0.68
Current smokers, % 0 7.32 7.52 0.52
Alcohol intake, g/day 3.42 (2.69) 8.08 (29.53) 5.56 (16.54) 0.16
I10701
N 110 428 493
Gender, % male 50.00 48.83 46.45 0.69
Age, y 49.48 (17.69) 47.57 (15.94) 49.65 (16.02) 0.13
Current smokers, % 4.55 8.18 7.30 0.43
Alcohol intake, g/day 4.87 (9.09) 5.44 (18.41) 6.97 (23.50) 0.42
I68477
N 91 456 483
Gender, % male 48.24 47.37 47.25 0.96
Age, y 48.33 (15.88) 49.13 (16.59) 49.07 (15.51) 0.73
Current smokers, % 12.09 7.24 6.63 0.19
Alcohol intake, g/day 3.24 (8.16) 6.06 (21.25) 6.70 (21.05) 0.33
{a=minor allele; A=major allele.
{P-values were derived from tests of null hypothesis that no group is different,
using a 1-way ANOVA for continuous traits or the x
2 test for categorical
variables.
doi:10.1371/journal.pone.0030732.t001
Table 2. BMI (kg/m
2; standard deviation) distribution of the
GOLDN study population by LRP-1 genotype.
Genotypes
a
P
b Padj
c
aa aA AA
C766T 30.41 (4.54) 29.03 (5.64) 28.05 (5.67) 0.28 .76
I10701 27.46 (5.84) 28.21 (5.65) 28.63 (5.62) 0.03 .09
I68477 29.15 (5.29) 28.24 (5.76) 28.24 (5.61) 0.24 .72
aa=minor allele; A=major allele.
bP-values were derived from mixed linear models with genotype frequency, age
and age
2, sex, smoking, total alcohol and center of data collection as
predictors, and BMI (logarithmically transformed) as the outcome within a
dominant model (AA/Aa vs. aa). BMI Data are presented that are back
transformed for easy interpretation.
cP-value adjusted after a Bonferroni correction.
doi:10.1371/journal.pone.0030732.t002
Table 3. ApoE genotypes by LRP-1 I10701 genotype.
Genotypes{ P{
aa aA AA
e2 carriers; % 11.82 10.28 10.34 .89
e4 carriers; % 27.27 25.93 25.35 .91
e3/e3 carriers; % 58.18 59.81 59.23 .95
doi:10.1371/journal.pone.0030732.t003
Table 4. Parameter estimates from linear regression models
looking at the effects of LRP-1 I10701 SNP and ApoE isoforms
on BMI in the GOLDN study population.
Beta (b)S E P
a
e2 carriers vs. e3/e3 ApoE genotype
LRP-1 I10701 genotype 20.01 0.01 0.26
ApoE isoform 0.004 0.01 0.29
Interaction term 20.02 0.02 0.93
e4 carriers vs. e3/e3 ApoE genotype
LRP-1 genotype 20.02 0.01 0.01
ApoE isoform 0.03 0.01 0.52
Interaction term 20.02 0.02 0.28
aP-values were derived from mixed linear models, specifying a Kenward Rogers
correction on the estimator, with LRP-1 I10701 SNP and ApoE genotype
frequency, an interaction between ApoE and LRP-1 genotype frequency, age
and age
2, sex, smoking, total alcohol and center of data collection as
predictors, and BMI (logarithmically transformed) as the outcome.
doi:10.1371/journal.pone.0030732.t004
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descent and it is not clear if these results generalize to other
ethnicities. In addition, replication is necessary as the finding of a
main effect of LRP-1 on BMI did not survive the correction for
multiple testing. Despite these limitations we provide evidence that
the LRP-1 locus contributes to variations in BMI, and that these
LRP-1 variations are not mediated by variations at the ApoE locus
in this relationship. This information is useful in starting to
understand the biological causes to differences in BMI, and
warrants replication in independent samples.
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